keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimers uk

keyword
https://www.readbyqxmd.com/read/29452684/evaluation-of-the-safety-tolerability-and-efficacy-of-pimavanserin-versus-placebo-in-patients-with-alzheimer-s-disease-psychosis-a-phase-2-randomised-placebo-controlled-double-blind-study
#1
Clive Ballard, Carol Banister, Zunera Khan, Jeffrey Cummings, George Demos, Bruce Coate, James M Youakim, Randall Owen, Srdjan Stankovic
BACKGROUND: Pimavanserin is a selective 5-HT 2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved for psychosis in patients with Alzheimer's disease. Therefore, we aimed to evaluate the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis. METHODS: We did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study...
March 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29413314/accelerated-long-term-forgetting-in-presymptomatic-autosomal-dominant-alzheimer-s-disease-a-cross-sectional-study
#2
Philip S J Weston, Jennifer M Nicholas, Susie M D Henley, Yuying Liang, Kirsty Macpherson, Elizabeth Donnachie, Jonathan M Schott, Martin N Rossor, Sebastian J Crutch, Christopher R Butler, Adam Z Zeman, Nick C Fox
BACKGROUND: Tests sensitive to presymptomatic changes in Alzheimer's disease could be valuable for clinical trials. Accelerated long-term forgetting-during which memory impairment becomes apparent over longer periods than usually assessed, despite normal performance on standard cognitive testing-has been identified in other temporal lobe disorders. We assessed whether accelerated long-term forgetting is a feature of presymptomatic autosomal dominant (familial) Alzheimer's disease, and whether there is an association between accelerated long-term forgetting and early subjective memory changes...
February 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29408778/increased-serum-levels-of-tnf-%C3%AE-and-decreased-serum-levels-of-il-27-in-patients-with-parkinson-disease-and-their-correlation-with-disease-severity
#3
Ebrahim Kouchaki, Reza Daneshvar Kakhaki, Omid Reza Tamtaji, Ehsan Dadgostar, Mohammad Behnam, Hassan Nikoueinejad, Hossein Akbari
OBJECTIVES: Immunological basis of neurodegenerative diseases including Alzheimer and Parkinson disease (PD) has some important roles in their pathogenesis. There are conflicting studies to serum level of TNF-α in PD. Also, according to our finding there is no report evaluating serum level of IL-27 in PD. This study correlates the serum level of those factors with severity of PD. PATIENTS AND METHODS: In this case-control study, 83 patients with PD and 83 healthy volunteers were enrolled...
January 31, 2018: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29397305/spatial-patterns-of-neuroimaging-biomarker-change-in-individuals-from-families-with-autosomal-dominant-alzheimer-s-disease-a-longitudinal-study
#4
Brian A Gordon, Tyler M Blazey, Yi Su, Amrita Hari-Raj, Aylin Dincer, Shaney Flores, Jon Christensen, Eric McDade, Guoqiao Wang, Chengjie Xiong, Nigel J Cairns, Jason Hassenstab, Daniel S Marcus, Anne M Fagan, Clifford R Jack, Russ C Hornbeck, Katrina L Paumier, Beau M Ances, Sarah B Berman, Adam M Brickman, David M Cash, Jasmeer P Chhatwal, Stephen Correia, Stefan Förster, Nick C Fox, Neill R Graff-Radford, Christian la Fougère, Johannes Levin, Colin L Masters, Martin N Rossor, Stephen Salloway, Andrew J Saykin, Peter R Schofield, Paul M Thompson, Michael M Weiner, David M Holtzman, Marcus E Raichle, John C Morris, Randall J Bateman, Tammie L S Benzinger
BACKGROUND: Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation, hypometabolism, and structural decline that precedes the onset of clinical dementia. These pathological features evolve both temporally and spatially in the brain. In this study, we aimed to characterise where in the brain and when in the course of the disease neuroimaging biomarkers become abnormal. METHODS: Between Jan 1, 2009, and Dec 31, 2015, we analysed data from mutation non-carriers, asymptomatic carriers, and symptomatic carriers from families carrying gene mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein (APP) enrolled in the Dominantly Inherited Alzheimer's Network...
January 31, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29379287/the-association-between-hippocampal-subfield-volumes-and-education-in-cognitively-normal-older-adults-and-amnestic-mild-cognitive-impairment-patients
#5
Dong Woo Kang, Hyun Kook Lim, Soo-Hyun Joo, Na Rae Lee, Chang Uk Lee
Objective: Previous research has indicated that there are potential associations between education and total hippocampal volume in the trajectory of Alzheimer's disease (AD). However, the correlation between education and hippocampal subfield volumes in the progression of AD has yet to be understood. This study examined the relationship between education, which is a standard proxy for cognitive reserve, and hippocampal subfield volumes in healthy and amnestic mild cognitive impairment (aMCI) groups...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29289576/botanicals-and-phytochemicals-active-on-cognitive-decline-the-clinical-evidence
#6
REVIEW
Arrigo F G Cicero, Federica Fogacci, Maciej Banach
Beyond the well-known effects on cognitive impairment of the Mediterranean diet, a number of studies have investigated the possible action on cognitive decline of different botanicals and phytochemicals, most of which are well-known anti-inflammatory or antioxidant agents with a good tolerability and safety profile. In particular, the current literature supports the use of Ginkgo biloba, resveratrol, epigallocatechin-3-gallate and l-theanine, Theobroma cacao, Bacopa monnieri, Crocus sativus and curcumin, which might have a positive impact on cognitive impairment used alone or in combination with other nutraceuticals or traditional drugs...
December 28, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29247073/comparative-effect-of-statins-on-the-risk-of-incident-alzheimer-disease
#7
Liliya Sinyavskaya, Serge Gauthier, Christel Renoux, Sophie Dell'Aniello, Samy Suissa, Paul Brassard
OBJECTIVE: To investigate whether fungus-derived statins are associated with a lower risk of incident Alzheimer disease (AD) compared with synthetic statins using real-world clinical practice data. METHODS: We identified a population-based retrospective cohort of patients aged ≥60 years newly prescribed a statin between January 1, 1994, and December 31, 2012, and followed until March 31, 2015, using the UK Clinical Practice Research Datalink. Statins were consecutively classified according to their type, lipophilicity, and potency...
January 16, 2018: Neurology
https://www.readbyqxmd.com/read/29227965/human-longevity-25-genetic-loci-associated-in-389-166-uk-biobank-participants
#8
Luke C Pilling, Chia-Ling Kuo, Kamil Sicinski, Jone Tamosauskaite, George A Kuchel, Lorna W Harries, Pamela Herd, Robert Wallace, Luigi Ferrucci, David Melzer
We undertook a genome-wide association study (GWAS) of parental longevity in European descent UK Biobank participants. For combined mothers' and fathers' attained age, 10 loci were associated (p<5*10-8), including 8 previously identified for traits including survival, Alzheimer's and cardiovascular disease. Of these, 4 were also associated with longest 10% survival (mothers age ≥90 years, fathers ≥87 years), with 2 additional associations including MC2R intronic variants (coding for the adrenocorticotropic hormone receptor)...
December 6, 2017: Aging
https://www.readbyqxmd.com/read/29223769/obstructive-sleep-apnoea-and-alzheimer-s-disease-in-search-of-shared-pathomechanisms
#9
REVIEW
D Polsek, N Gildeh, D Cash, R Winsky-Sommerer, S C R Williams, F Turkheimer, G D Leschziner, M J Morrell, I Rosenzweig
Alzheimer's disease (AD) is a significant public health concern. The incidence continues to rise, and it is set to be over one million in the UK by 2025. The processes involved in the pathogenesis of AD have been shown to overlap with those found in cognitive decline in patients with Obstructive Sleep Apnoea (OSA). Currently, the standard treatment for OSA is Continuous Positive Airway Pressure. Adherence to treatment can, however, be an issue, especially in patients with dementia. Also, not all patients respond adequately, necessitating the use of additional treatments...
December 6, 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/29211061/erratum-to-prediction-of-treatment-response-to-donepezil-using-automated-hippocampal-subfields-volumes-segmentation-in-patients-with-mild-alzheimer-s-disease
#10
Yoo Hyun Um, Tae-Won Kim, Jong-Hyun Jeong, Ho-Jun Seo, Jin-Hee Han, Seung-Chul Hong, Chang-Uk Lee, Hyun Kook Lim
[This corrects the article on p. 698 in vol. 14.].
November 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/29164603/18f-pet-with-florbetapir-for-the-early-diagnosis-of-alzheimer-s-disease-dementia-and-other-dementias-in-people-with-mild-cognitive-impairment-mci
#11
REVIEW
Gabriel Martínez, Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Xavier Bonfill Cosp, Leon Flicker
BACKGROUND: 18F-florbetapir uptake by brain tissue measured by positron emission tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using amyloid biomarkers tests like 18F-florbetapir...
November 22, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29164602/18f-pet-with-flutemetamol-for-the-early-diagnosis-of-alzheimer-s-disease-dementia-and-other-dementias-in-people-with-mild-cognitive-impairment-mci
#12
REVIEW
Gabriel Martínez, Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Leon Flicker, Xavier Bonfill Cosp
BACKGROUND: 18F-flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and the confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-flutemetamol...
November 22, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29164600/18f-pet-with-florbetaben-for-the-early-diagnosis-of-alzheimer-s-disease-dementia-and-other-dementias-in-people-with-mild-cognitive-impairment-mci
#13
REVIEW
Gabriel Martínez, Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Leon Flicker, Xavier Bonfill Cosp
BACKGROUND: 18 F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18 F-florbetaben...
November 22, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29142140/imaging-and-csf-analyses-effectively-distinguish-cjd-from-its-mimics
#14
Peter Rudge, Harpreet Hyare, Alison Green, John Collinge, Simon Mead
OBJECTIVE: To review clinical and investigation findings in patients referred to a specialist prion clinic who were suspected to have sporadic Creutzfeldt-Jakob disease (sCJD) and yet were found to have an alternative final diagnosis. METHODS: Review the clinical findings and investigations in 214 patients enrolled into the UK National Prion Monitoring Cohort Study between October 2008 and November 2015 who had postmortem confirmed sCJD and compare these features with 50 patients referred over the same period who had an alternative final diagnosis (CJD mimics)...
November 15, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29089631/impact-of-amyloid-burden-on-regional-functional-synchronization-in-the-cognitively-normal-older-adults
#15
Dong Woo Kang, Woo Hee Choi, Won Sang Jung, Yoo Hyun Um, Chang Uk Lee, Hyun Kook Lim
Previous studies have shown aberrant functional connectivity in preclinical Alzheimer's disease (AD). However, the effects of beta-amyloid (Aβ) retention on regional functional synchronization in cognitively normal older adults still remain unclear. The aim of this study was to explore the distinctive association pattern between Aβ retention and regional functional synchronization in cognitively normal older adults. Sixty-one older adults with normal cognition underwent functional magnetic resonance imaging and regional functional synchronizations were quantified using regional homogeneity (ReHo)...
October 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29066367/brain-metabolic-correlates-of-csf-tau-protein-in-a-large-cohort-of-alzheimer-s-disease-patients-a-csf-and-fdg-pet-study
#16
Agostino Chiaravalloti, Gaetano Barbagallo, Maria Ricci, Alessandro Martorana, Francesco Ursini, Pasqualina Sannino, Georgios Karalis, Orazio Schillaci
AIMS: Physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especially the role of amyloid β and tau pathology in the development of the disease are still matter of debate. Changes in tau and amyloid β peptide concentration in cerebrospinal fluid (CSF) and hypometabolic patterns at fluorine-18 fluorodeoxyglucose (18F-FDG) PET scanning are considered as biomarkers of AD. The present study was aimed to evaluate the relationships between the concentrations of CSF total Tau (t-Tau), phosphorilated Tau (p-Tau) and Aβ1-42 amyloid peptide with 18F-FDG brain distribution in a group of patients with AD...
January 1, 2018: Brain Research
https://www.readbyqxmd.com/read/29054022/a-shape-code-nanoplasmonic-biosensor-for-multiplex-detection-of-alzheimer-s-disease-biomarkers
#17
Hanbi Kim, Jong Uk Lee, Sojin Song, Soohyun Kim, Sang Jun Sim
Alzheimer's disease (AD) is a neurodegenerative disease associated with the loss of nerve cells in the brain. The disease is affected by multifactorial pathways and leads to changes in related biomolecular levels as AD progresses. Therefore, AD should be diagnosed with combined detection of several lesions to improve accuracy. Amyloid beta 1-40, 1-42 and τ (tau) protein are milestones in AD pathology and can be used as main screening and diagnostic target markers. Here, we suggest a highly selective biosensor for detection of AD core biomarkers on one platform through distinct localized surface plasmon resonance (LSPR) depending on gold nanoparticles shapes, called a shape-code biosensor...
March 15, 2018: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/29042898/prediction-of-treatment-response-to-donepezil-using-automated-hippocampal-subfields-volumes-segmentation-in-patients-with-mild-alzheimer-s-disease
#18
Yoo Hyun Um, Tae-Won Kim, Jong-Hyun Jeong, Ho-Jun Seo, Jin-Hee Han, Seung-Chul Hong, Chang-Uk Lee, Hyun Kook Lim
Previous studies reported some relationships between donepezil treatment and hippocampus in Alzheimer's disease (AD). However, due to methodological limitations, their close relationships remain unclear. The aim of this study is to predict treatment response to donepezil by utilizing the automated segmentation of hippocampal subfields volumes (ASHS) in AD. Sixty four AD patients were prescribed with donepezil and were followed up for 24 weeks. Cognitive function was measured to assess whether there was a response from the donepezil treatment...
September 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/29036821/estimated-glomerular-filtration-rate-is-not-associated-with-alzheimer-s-disease-in-a-northern-ireland-cohort
#19
Euan N Paterson, Michael A Williams, Peter Passmore, Giuliana Silvestri, Tom J MacGillivray, Alexander P Maxwell, Gareth J McKay
BACKGROUND: Alzheimer's disease (AD) prevalence is increasing globally and typically progresses for several years prior to clinical presentation of dementia. Renal dysfunction and vascular disease have been reported in association with dementia in several cross-sectional and longitudinal studies, and may contribute to AD risk. Experimental and observational studies suggest amyloid-β (Aβ) clearance may be impaired in chronic kidney disease (CKD) indicating a mechanism for increased AD risk...
October 11, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29018162/clinical-utility-of-amyloid-pet-imaging-with-18-f-florbetapir-a-retrospective-study-of-100-patients
#20
Christopher James Carswell, Zarni Win, Kirsty Muckle, Angus Kennedy, Adam Waldman, Gemma Dawe, Tara D Barwick, Sameer Khan, Paresh A Malhotra, Richard J Perry
BACKGROUND AND OBJECTIVE: Amyloid-positron emission tomography (PET) imaging (API) detects amyloid-beta pathology early in the course of Alzheimer's disease (AD) with high sensitivity and specificity. (18)F-florbetapir (Amyvid) is an amyloid-binding PET ligand with a half-life suitable for clinical use outside of the research setting. How API affects patient investigation and management in the 'real-world' arena is unknown. To address this, we retrospectively documented the effect of API in patients in the memory clinic...
October 10, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
keyword
keyword
19559
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"